Risk prediction of acute kidney injury by [TIMP-2]•[IGFBP7]

Drugs Today (Barc). 2017 Jun;53(6):349-356. doi: 10.1358/dot.2017.53.6.2604170.

Abstract

Acute kidney injury (AKI) is a common syndrome with increased mortality, a heavy burden of illness and high cost. The Kidney Disease Improving Global Outcomes (KDIGO) criteria for staging of AKI have been validated in large patient cohorts and classify AKI into three stages. In order to achieve prevention or early therapy, the focus of scientific interest is early detection and risk prediction of AKI. The combination of the two cell cycle arrest markers [TIMP-2]·[IGFBP7] in the urine shows good results in the risk prediction of AKI in different clinical settings (intensive care medicine, sepsis, cardiac surgery, emergency department). Clinical use is currently being tested in different randomized intervention studies.

Keywords: Acute kidney injury; Biomarkers; IGFBP7; TIMP-2.

Publication types

  • Review

MeSH terms

  • Acute Kidney Injury / blood
  • Acute Kidney Injury / urine*
  • Biomarkers
  • Cardiac Surgical Procedures
  • Clinical Trials as Topic
  • Creatinine / blood
  • Emergencies
  • Humans
  • Insulin-Like Growth Factor Binding Proteins / urine*
  • Postoperative Complications / urine
  • Predictive Value of Tests
  • Risk Assessment
  • Sepsis / urine
  • Tissue Inhibitor of Metalloproteinase-2 / urine*
  • Urinalysis / methods

Substances

  • Biomarkers
  • Insulin-Like Growth Factor Binding Proteins
  • TIMP2 protein, human
  • insulin-like growth factor binding protein-related protein 1
  • Tissue Inhibitor of Metalloproteinase-2
  • Creatinine